Five Key Takeaways From Merck’s Q2 Earnings Release
Keytruda and Gardasil lead Merck’s growth story, although Lagevrio’s ongoing decline placed a drag on quarterly performance. Lung cancer is driving Keytruda’s momentum outside the US.
Keytruda and Gardasil lead Merck’s growth story, although Lagevrio’s ongoing decline placed a drag on quarterly performance. Lung cancer is driving Keytruda’s momentum outside the US.